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Programmable nucleases like transcription activator-like effector 
nucleases (TALENs) and RNA-guided engineered nucleases (RGENs) 
are broadly used for engineering of genome in various cells and organisms. 
TALENs are recently developed fusion proteins of a modular DNA-
binding TALE repeat domain and a catalytic nuclease domain of FokI 
restriction endonuclease. In this thesis, I designed and synthesized highly 
active TALENs to target the progesterone immunomodulatory binding 
1 
factor 1 (Pibf1) and the selenoprotein W, muscle 1 (Sepw1) gene. Non-
homologous end-joining (NHEJ) mediated indel mutations were detected 
in transfected mouse cells with plasmids encoding these TALENs and 
knock-out mice of these genes were successfully generated via embryo 
microinjection. RGENs are efficient artificial endonucleases using 
CRISPR/Cas system which is a prokaryotic immune system. In this study, 
I have designed RGENs to target inverted region of the blood coagulation 
factor VIII (F8) gene that is known as a major cause of severe hemophilia 
phenotype. When two RGENs were used to generate double-strand 
breaks (DSB) at their endogenous target loci in wild-type Hela cells, the 
large chromosomal segment up to 600-kbp is inverted. Furthermore, the 
inverted region of induced pluripotent stem cells (iPSC) from hemophilia 
patients is also successfully reverted via these RGENs and mRNA 
expression of F8 is recovered. TALENs and RGENs have enabled targeted 
genome editing easily and efficiently. These technologies will be very 
useful systems for research of gene functions and correcting the genetic 
causes of many diseases.  
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Chapter 1. Efficient TALEN-mediated Gene 























Elucidating gene function and identifying gene products are the 
great interest of many scientists. Although human and mouse genome have 
been sequenced, the network and function of most genes are still not 
uncovered. 
Specific target gene disruption is a powerful method of elucidating 
gene function in vivo. For example, targeted gene knockdown by RNA 
interference (RNAi) is a rapid, inexpensive, and high-throughput system 
for reverse genetic approaches. RNAi was first discovered in the worm 
(Fire et al. 1998) and many researchers have recently reported 
successful siRNA-mediated knockdown of mammalian genes (Elbashir, S. 
M. et al. 2001; Ohta, T. et al. 2002; Moskalenko, S. et al. 2002). However, 
RNAi is incomplete because of temporarily knockdown rather than gene 
knockout, varies between experiments and laboratories, and even has 
unpredictable off-target effects (Krueger et al. 2007; Jackson et al. 
2003).  
Introducing a double-strand break (DSB) in a eukaryotic 
chromosomal DNA can stimulate nonhomologous end-joining (NHEJ) 
repair system and produce localized indel mutations at the break (Jeggo 
1998; van Gent et al. 2001) which can lead to gene disruption. Thus, 
targeted cleavage of specific DNA sequence in vivo is a very powerful 
research technique for studying genome function. Zinc finger nucleases 
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(ZFNs) are engineered nucleases generated by fusing a zinc finger DNA-
binding domain and a DNA-cleavage domain of FokI restriction enzyme 
(Kim et al, 1996). Because zinc finger DNA-binding domains can be 
designed to target a specific sequence, introducing genetic modifications 
in a target gene can be possible. Actually, targeted genome editing is 
successfully performed in mammalian, plant, and other higher eukaryotic 
cells and organisms (Bibivoka et al. 2002, 2003; Lloyd et al. 2005; Urnov 
et al. 2005; Wright et al. 2006; Beumer et al. 2006; Doyon et al. 2008; 
Maeder et al. 2008; Meng et al. 2008; Santiago et al. 2008) 
Although ZFNs are very useful tools for gene editing, there are 
some complicating issues about the design and application of ZFNs. First, 
it is difficult in some cases to design ZFNs that have the binding 
specificities at the desired target sites (Ramirez et al. 2008). A zinc finger 
protein can recognize three base pairs specifically, but assembled zinc 
finger proteins into arrays do not always recognize desired sequences 
(Lam et al. 2011). Second, some ZFNs have cytotoxicity, presumably due 
to making DSB at off-target sites (Cornu et al. 2008; Radecke et al. 2010; 
Pruett et al. 2008). Although this problem has been solved to some extent 
with using engineered FokI heterodimers (Szczepek et al. 2007; Miller et 
al. 2007; Doyon et al. 2011), off-target effect of ZFNs is a problem that 
is still concern. 
Transcription activator-like effectors (TALEs) are natural 
modular proteins secreted by pathogens of plants like Xanthomonas to 
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modulate gene expression in host plants and to facilitate bacterial survival. 
(Boch et al. 2010; Bogdanove et al. 2010) Repeat monomers of TALEs 
differ from each other mainly in amino acid positions 12 and 13, and a 
strong correlation have been revealed between pairs of amino acids at 
positions 12 and 13 and the corresponding DNA nucleotide in the TALE-
binding site: NI to A, HD to C, NG to T, NN to G (Boch et al. 2009). Thus, 
like ZFN, TALEN which is a novel fusion protein of a TALE protein and a 
DNA-cleavage domain of FokI restriction enzyme enables the targeted 
alteration at a predetermined locus (Cermak et al. 2011; Miller et al. 2011; 
Sander et al. 2011). 
Engineered nuclease-mediated mutagenesis in zygotes is a 
potential alternative to conventional gene targeting in mice. Although 
microinjection of engineered ZFNs in embryos was used to generate gene 
knockouts in the mouse successfully (Carbery, I.D. et al. 2010), gene 
knockout mice have yet to be created using TALENs. In this thesis, I 
designed and synthesized highly active TALENs to target the 
progesterone immunomodulatory binding factor 1 (Pibf1) gene and the 
selenoprotein W, muscle 1 (Sepw1) gene in mice. In NIH3T3 mouse cell 
line, TALEN activity is confirmed by T7 Endonuclease 1 (T7E1) assay 
and sequencing and knock-out mice of these genes were successfully 




Materials and Methods 
 
1. Plasmid encoding TALENs 
For Pibf1-specific TALEN plasmids, oligonucleotides encoding 
each TALE repeat module were synthesized and subcloned into modularly 
assembled repeat arrays, with the Δ153/+16 N- and C-terminal 
truncation domains of AvrBs3 and the FokI nuclease domain. FokI 
nuclease domains of TALENs used in this study were the obligatory 
heterodimer nucleases Sharkey RR and Sharkey DAS (Guo et al. 2010). 
The Sepw1-specific TALEN plasmids were obtained from ToolGen, Inc. 
(South Korea). The complete sequences of the TALENs targeting Pibf1 















Figure 1. Target sequences of Pibf1-TALEN. (a) The target region of 
Pibf1-TALEN in the mouse Pibf1 locus. Pibf1-TALEN binding sites: red, 
TL1-RR; blue, TL2-DAS. (b and c) Nucleotide and amino-acid 




















Figure 2. Target sequences of Sepw1-TALEN. (a) The target region of 
Sepw1-TALEN in the mouse Sepw1 locus. Sepw1-TALEN binding sites: 
red, Left-DAS; blue, Right-RR. (b and c) Nucleotide and amino-acid 




















2. Non-homologous end-joining (NHEJ) reporter assay 
NHEJ reporter plasmids used in this study were constructed as 
previously described (Kim et al. 2011). In brief, oligonucleotides 
containing each target site were synthesized (Bioneer, Inc., Korea), and 
the surrogate reporters were constructed by cloning annealed 
oligonucleotides into vector pRGS (ToolGen, Inc., Korea). Each surrogate 
reporter was transfected into HEK-293 cells with or without TALEN-
expressing constructs using Lipofectamine 2000 (Invitrogen), and the 
reporter-gene activities were measured by flow cytometry 3 days after 
transfection using a FACSCanto flow cytometer (BD Bioscience) or C6 
flow cytometer (Accuri). 
 
 
3. Transient transfection and T7 endonuclease I (T7E1) 
assay 
NIH3T3 cells were transfected with TALEN pairs using 
Turbofect (Fermentas) according to the manufacturer’s instructions. 
The genomic DNA samples were extracted 72 hours after transfection 
using the Genomic DNA Extraction Kit (iNtRON Biotechnology) as 
described by the manufacturer. To screen F0 mice with targeted Pibf1 or 
Sepw1 alleles, genomic DNA samples were prepared from tail biopsies. 
The T7E1 assays were performed as previously described (Kim et al. 
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2009). Briefly, the genomic region encompassing the TALEN target site 
was PCR-amplified, melted, and re-annealed to form heteroduplex DNA, 
which was treated with 5 units of T7 endonuclease 1 (New England 
Biolabs) for 15 min at 37°C and then analyzed by agarose gel 
electrophoresis. To evaluate non-specific effects of TALENs, potential 
off target sites were predicted as previously described (Doyle et al. 2012), 
and T7E1 assays were performed using genomic DNA samples from F0 
mutant mice. 
 
4. Sequence analyses and genotyping 
To confirm the genotype of F0 mice detected by T7E1 assays, 
further analyses were conducted as follows. For fluorescence PCR (fPCR), 
genomic DNA was subjected to PCR analysis using HiPi Plus DNA 
polymerase (ELPIS) and 5′-carboxyfluorescein–labeled primers. The 
PCR amplicons were studied using an ABI 3730xl DNA analyzer. For 
sequencing, PCR products were cloned using the T-Blunt PCR Cloning Kit 
(SolGent Co., Ltd. Korea), and mutations were identified by direct 
sequencing. For routine PCR genotyping of F1 progeny from selected F0 
founder mice, the following primer pair was designed to amplify an 80-bp 
PCR product from wild-type mice and smaller products from TALEN-
induced mutant alleles: 5'- GTTTGGAAACAACCATTCATACAG -3' and 
5'- CGATTAACTGCCTGGTGATTTTG -3'. For kinetic analysis at the 
one-cell stage, embryos were collected 12 hours after injection of Pibf1-
23 
TALEN mRNA and processed using the GenomePlex Single Cell Whole 
Genome Amplification Kit according to the manufacturer’s instructions 
(Sigma). 
 
5. Western blot analysis 
Proteins were extracted from tissue samples by homogenizing in 
a lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% 
NP-40, 0.5% deoxycholic acid, 0.1% SDS) supplemented with 
proteasome and phosphatase inhibitors, and western blot analysis of 
Sepw1 was performed with 30 μg of proteins using a Selenoprotein W-
specific rabbit polyclonal antibody (Novus Biologicals, Littleton, Colorado, 
USA) according to manufacturer’s instructions. 
 
6. Preparation of TALEN mRNAs 
Pibf1- and Sepw1-TALEN mRNAs were prepared using the 
mMESSAGE mMACHINE T7 Ultra kit (Ambion) according to the 
manufacturer’s instructions and diluted to working concentrations in 
diethyl pyrocarbonate (DEPC, Sigma)–treated injection buffer (0.25 mM 





7. Microinjection of TALEN mRNAs into mouse embryos 
All animal experiments were performed in accordance with the 
Korean Food and Drug Administration (KFDA) guidelines. Protocols were 
reviewed and approved by the Institutional Animal Care and Use 
Committees (IACUC) of the Laboratory Animal Research Center at Yonsei 
University (Permit Number: 2012-0087). All mice were maintained in the 
specific pathogen–free facility of the Laboratory Animal Research Center 
at Yonsei University. 
C57BL/6 (B6) and ICR mouse strains were used as embryo 
donors and foster mothers, respectively. Female B6 mice (7–8 weeks old) 
were super-ovulated by intraperitoneal injections of 5 IU pregnant mare 
serum gonadotropin (PMSG, Sigma) and 5 IU human chorionic 
gonadotropin (hCG, Sigma) at 48-hour intervals. The super-ovulated 
female mice were mated to B6 stud males, and fertilized embryos were 
collected from oviducts. 
TALEN mRNAs was injected into the cytoplasm of fertilized eggs 
with well recognized pronuclei in M2 medium (Sigma) using Piezo-driven 
micromanipulator (Prime Tech). For Pibf1-TALEN, two different 
concentrations (20 and 50 ng/ul of Pibf1-TALEN mRNA) were used, 
whereas a single dose of Sepw1-TALEN mRNA (50 ng/ul) was injected. 
After incubation at 37℃ for 24 hours, two-cell embryos were selected 
and transferred into the oviducts of pseudopregnant foster mothers. 
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8. Fluorescence PCR 
Genomic Genomic DNA (100 ng per reaction) was subjected to 
PCR analysis using HiPi Plus DNA polymerase (ELPIS) and 5′-
carboxyfluorescein–labeled primers. The PCR amplicons were studied 






















1. Activity test of TALENs in mouse cell line 
To target these genes in the mouse genome, I designed and 
synthesized highly active TALENs specific to exon 2 of Pibf1 (Pibf1- 
TALEN; Figure 1) and exon 1 of Sepw1 (Sepw1-TALEN; Figure 2). To 
test the efficiency each TALENs, I transfected human embryonic kidney 
293 (HEK-293) cells with these TALEN plasmids and a surrogate 
reporter (Kim et. al 2011). Flow-cytometric analyses measuring 
nonhomologous-end-joining (NHEJ) activity induced by Pibf1-TALEN 
and Sepw1-TALEN showed that about 13% and 21.5% of cells had 
frameshift indel mutations in the reporter plasmid, respectively (Figure 
3).  
I also transfected Pibf1-TALEN plasmids into NIH3T3 mouse 
cell line. T7E1 assay and sequencing analysis showed that these TALENs 













Figure 3. The specific activity of Pibf1-TALEN. (a) Flow-cytometric 
analyses measuring nonhomologous-end-joining (NHEJ) activity 
induced by Pibf1-TALEN in human embryonic kidney 293 (HEK-293) 
cells. Populations in red (mRFP) indicated transfected cells, and GFP 
expression showed NHEJ activity. (b) T7E1 assays using NIH3T3 cells 
transfected with empty vector (EV) or Pibf1-TALEN (TALEN). The 
arrow indicates the product of T7E1 digestion. (c) Direct sequence 
analysis of the target region of the Pibf1 locus of NIH3T3 cells, showing 
frameshift mutations induced by Pibf1-TALEN. Sequences in red indicate 
the TALEN binding sites. “-” denotes deleted nucleotides. (d) The 
specific activity of Sepw1-TALEN. Flow-cytometric analyses measuring 
NHEJ activity induced by Sepw1-TALEN in HEK-293 cells. Populations 
in red (mRFP) indicate transfected cells, and concomitant GFP expression 
reflects NHEJ activity. (e) Schematic overview of surrogate reporter 
system (Kim et al. 2011). When a double-strand break is introduced into 
the target sequence by programmable nucleases like TALENs, the break 
is repaired by nonhomologous end-joining (NHEJ), which often causes 
frameshift mutations. Such mutations can render eGFP in frame with 






2. Generation of TALEN-mediated mutant mice 
Each TALEN mRNA pair was injected into the cytoplasm of 
mouse pronuclear-stage embryos to produce mutant founders (F0) with 
mutations in Pibf1 (Figure 4, 5, and Table 1) or Sepw1 (Figure 6 and 
Table 2). Most TALEN-induced mutations were deletions of variable 
lengths that induced frameshifts in the Pibf1 and Sepw1 genes (Figure 
4~6). In-frame mutations, as a result of deletions and substitutions of 
specific amino-acid residues, were also frequent (Figure 4). Such 
mutations will be beneficial for studying putative domain- or amino acid 
residue–specific functions of the gene products. Insertional mutations 
were only observed in two instances (Figure 5).  
To investigate the dose-dependent effects of the TALEN mRNAs, 
two different concentrations of Pibf1-TALEN mRNA (50 ng/μl and 20 
ng/μl) were used, yielding 29 mutants (55.8%) from 52 newborns (Figure 
4, 5, and Table 1). Bi-allelic mutations were observed in seven mutant 
mice (Figure 4, 5). The mutation rate was approximately proportional to 
the injection dose of Pibf1-TALEN mRNA. Injection of a high 
concentration (50 ng/μl) of Pibf1-TALEN mRNA yielded 10/13 (76.9%) 
mutant F0 mice, whereas injection of a lower dose (20 ng/μl) yielded 
19/39 (48.7%) F0 mutant mice (Table 1). Bi-allelic mutations were also 
found more frequently in the high-dose (6/8 F0) than in the low-dose 
(1/19 F0; Figure 4, 5, and Table 1) group, indicating that Pibf1-TALEN 
activity was dose dependent. Furthermore, relatively large deletions were 
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more frequently observed in mutant founders obtained by high-dose 
injection than in those by low-dose injection (Figure 4, 5). 
In contrast to the mutation rate, the number of mutant mice 
produced by the low dose injection (19 mutants/176 transplanted embryos, 
10.8%) was ~2.5 fold larger than the number produced by the high-dose 
injection (10 mutants/243 transplanted embryos, 4.1%; Table 1). This 
phenomenon is reminiscent of the toxicity of zinc-finger nucleases (ZFNs) 
induced by generation of nonspecific double-strand breaks at off-target 
sites (Szczepek et al. 2007). Indeed, IgM mutant rats obtained by 
intracytoplasmic injection of IgM-TALEN mRNA had modifications at an 
off-target site (Tesson et al. 2011). Although off-target effects of 
Pibf1-TALEN was not detected by T7E1 assays (Table 3 and Figure 7), 
it cannot be ruled out the possibility that nonspecific effects might have 
caused embryonic toxicity. 
To validate TALEN-induced mutations, it is measured the level 
of Sepw1 protein in tail biopsies. No expression of Sepw1 protein was 
detected in a Sepw1 mutant founder possessing bi-allelic null mutations 









Figure 4. Generation of TALEN-mediated Pibf1 mutant mice. (a) T7 
endonuclease I (T7E1) assays were conducted using genomic DNA from 
pronuclear-stage embryos intra-cytoplasmically injected with Pibf1-
TALEN mRNA (50 ng/μl). The arrow indicates the size of T7E1-
digested DNA fragments. *Cannibalized mice. (b) DNA sequences of the 
Pibf1 locus from live F0 mice identified by T7E1 assays in b. ‘-’ 
denotes deleted nucleotides. Underlined sequences in lower case 










Figure 5. Generation of Pibf1 mutant mice by intra-cytoplasmic injection 
of PN-stage embryos with a low dose (20 ng/ul) of Pibf1-TALEN mRNA. 
(a) T7E1 assays. The numbers in blue denote founder mice harboring 
mutations in the Pibf1 locus. Arrows indicate the products of T7E1 
digestion. (b) Fluorescence PCR (fPCR) analyses. †5bp longer than its 
sequence in c. Note that F0 mice #34 and #38 are genetically mosaic. (c) 
DNA sequences of the Pibf1 locus in selected founder mice denoted in red 
in b. “-” denotes deleted nucleotides. *Note that Δ18-bp allele observed 




























50 276 263(95.3%) 262(99.6%) 243 13(5.3%)† 10(76.9%)†† 
20 183 176(96.2%) 176(100%) 176 39(22.2%)† 19(48.7%) 
 
Percentages were calculated using the number in each column as the 
numerator and the number in the column to its left as the denominator. 
*Determined by T7E1 assays. †Two pups were cannibalized at birth. †
†T7E1 assays were conducted using genomic DNA samples from 














Figure 6. Generation of Sepw1 mutant mice by intra-cytoplasmic injection 
of PN stage embryos with a high dose (50 ng/ul) of Sepw1-TALEN 
mRNA. (a) T7E1 assays for F0 screen. *, founder mice selected for direct 
sequence analyses shown in b. (b) DNA sequences of the Sepw1 locus in 
founder mice. Sequences in red indicate TALEN binding sites; blue 
indicates the start codon (ATG). Underlined sequences in lowercase 
represent nucleotide substitutions. F0 mice #4 & #9 are genetically 
mosaic. Note that Δ3 allele of F0 mouse #5 may have an upstream start 



















50 131 127(96.9%) 125(98.4%) 125 9(7.2%)† 6(66.7%)†† 
 
The percentages were calculated using the number in each column as the 
numerator and the number in the column to its left as the denominator. 
†Five pups were cannibalized at birth. ††T7E1 assays were conducted 


































* Putative binding sequences are in bold. Identical nucleotides are in 
uppercase. 













Figure 7. T7E1 assays examining the putative off-target effects of Pibf1-
TALEN. The integrity of potential off-target sites listed in Table 3 was 













(by Lee K. in Yeungnam Univ.) 
Figure 8. Expression level of Sepw1 protein in mutant mice. Western blot 
analysis of Sepw1 protein in tail biopsies of founders #3 & # 5 possessing 
bi-allelic null mutations in Sepw1 locus. A very weak signal from F0 
mouse #5 may indicate the inadequate translational product from Δ3 
allele indicated in Figure 6. Kidney as a tissue expressing a low level of 








3. Germ line transmission of mutations 
To confirm that mutations induced by TALENs were inherited to 
F1 progeny, three F0 Pibf1 mutants were crossed to wild-type mice and 
genotypes of the F1 offspring were determined. All the mutations 
observed in F0 mice were transmitted through the germline (Figure 9). 
These results indicate that TALEN-introduced mutant alleles were stably 



















(by Sung YH. in Yonsei Univ.) 
Figure 9. Germ-line transmission of TALEN-induced Pibf1 mutant alleles. 
Founder mice harboring TALEN-induced mutations were crossed to 
wild-type mice, and the genotypes of their F1 progeny were determined 









4. Activity of TALENs at the one cell stage 
Mosaicism was rarely detected in both Pibf1 (Figure 4, 5) and 
Sepw1 mutants (Figure 6), indicating that TALENs are primarily active at 
the one cell stage. To demonstrate that Pibf1-TALEN is active at this 
stage, the whole genomes of one-cell embryos was amplified before 
initiation of the first cell division and assessed the alteration of the target 
region in the Pibf1 locus. PCR genotyping and sequencing revealed 
deletions in the Pibf1 locus, even in one-cell embryos (Figure 10). I 
conclude that TALEN activity in one-cell embryos is sufficient to induce 
mutations. 
The occurrence of mosaicism in F0 would be predicted to result 
from sustained TALEN activity during later embryogenesis or re-
cleavage of already-modified alleles (Tesson et al. 2011). Because the 
first round of DNA replication begins after pronuclei become visibly 
evident under a stereomicroscope (Adenot et al. 1997), the presence of 
mosaic mutants would not necessarily prove that TALENs act at the two-
cell stage or later. If TALEN activity were sustained or delayed until the 
late one-cell stage, when the embryo possesses 4N DNA content before 
cell division, up to four different mutant alleles would be produced. No 
more than three different alleles were found among the Pibf1 (Figure 4, 
5) or Sepw1 mutant founders (Figure 6). These results support the 




(by Sung YH. in Yonsei Univ.) 
Figure 10. TALEN induces mutations in the Pibf1 locus in one-cell 
embryos. Embryos were harvested 12 hours after intra-cytoplasmic 
injection of PN-stage embryos with Pibf1-TALEN mRNA. (a) PCR 
genotyping after whole genome amplification (WGA). WT, wild-type; KO, 
founder #1 (Δ21, bi-allelic mutant); NC, negative control (human 
genomic DNA); no inj., embryos that were not injected with Pibf1-TALEN 
mRNA. (b) DNA sequences of PCR products (#1 and #2 in (a)) exhibiting 
deletions in the Pibf1 locus in DNA from one-cell embryos. Sequences in 









In this study, knockout of the Pibf1 and Sepw1 gene were 
successfully generated via transcription activator-like effector nucleases 
in NIH3T3 cell line and mice. Efficiency of yielding mutant mice is up to 
76.9% depending on mRNA injection dose and bi-allelic mutations were 
also found very frequently without any off-target effects.  
Efficient and precise genome engineering in living cells and 
organism hold great promise in both basic and applied research. These 
technologies exploit the ability of engineered nucleases to cause 
chromosomal DNA double-stranded breaks (DSBs) and stimulate the 
subsequent repair mechanisms like non-homologous end-joining (NHEJ) 
and homologous recombination (HR). NHEJ repair pathway results in 
insertion and deletion mutations in the targeted loci, whereas HR with 
donor DNA including homologous sequences of target region can generate 
replacement of target sequences. Although HR efficiency had not been 
tested in this study, recent papers report that HR via TALENs is very 
successful in many cells and organisms (Miller et al. 2011; Zu et al. 2013; 
Haibao Zhu et al. 2013; Katsuyama et al. 2013; Shin et al. 2014) including 
mice (Kasparek et al. 2014). Accordingly, TALEN technology has 
significant potential in experimental biology. 
Zinc finger nuclease (ZFN) is also useful tool for genome 
engineering, but widespread adoption of ZFNs is hampered by some 
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problems. Zinc finger recognize 3-bp subsites and up to 64 different 
modules are required to assemble zinc finger array for recognizing all of 
64 triplet bases. Unfortunately, unique zinc fingers targeting some 3-bp 
subsites are very hard to design (Maeder et al. 2008; Sander et al. 2011). 
Whereas, one TALE repeat module can recognize just single base pair and 
only four different modules are needed for making TALENs. Rearranging 
array of TAL modules, TALEN can recognize any wanted DNA sequences. 
Together with toxicity problem of ZFNs discussed above (Miller et al. 
2007; Cornu et al. 2008; Radecke et al. 2010), TALEN is more convenient 
and useful method for genome engineering. 
In this study, bi-allelic mutant of mice were frequently generated 
by TALENs (Figure 4~6) which means TALEN is active at the one cell 
stage. Although not in all tested embryos, activity of TALEN at this stage 
was detected even in low mRNA dose condition (Figure 10). If Pibf1-
TALEN protein is still active after the first cleavage of one-cell embryos, 
it should mutate the target locus independently in each nucleus of the two 
blastomeres, thereby frequently generating mosaic animals. However, 
predominantly mono-allelic Pibf1 mutations were produced in the low-
dose experiment, indicating that the activity of Pibf1-TALEN was not 
sustained in blastomeres at the two-cell stage. This pattern is 
reminiscent of the maternal-to-zygotic transition (MZT) that actively 
eliminates maternally provided gene products (Tadros W et al. 2009). 
Although more detailed studies should be conducted that are designed to 
46 
provide more direct evidence for TALEN activity at different 
developmental stages, results of this study suggest that TALEN activity 
is not likely to be maintained after the first cleavage of one cell embryos 
which means it is very easy to generate knockout mice with TALENs.  
In summary, this study establishes that TALEN mediated gene 
targeting is an efficient method for creating heritable null mutations in a 
specific locus of the mouse genome without any off-target effects. 
Furthermore, TALEN activity in one-cell embryos is sufficient to induce 
mutations. Taken together, these data suggest that TALEN-mediated in 
vivo mutagenesis might expedite the creation of genetically engineered 
mouse models and thereby help to accelerate functional genomic research. 
Thus, TALEN technology will be a powerful option that will facilitate 












Chapter 2. Efficient gene correction of F8 























Gene therapy is an experimental technique to correct defective 
genes in patient’s cells instead of using drugs or surgery. There are 
several gene therapeutic ways that: 1) gene addition approaches in which 
the therapeutic cDNA is expressed (Cappelli et al. 2010), 2) knocking out 
a mutated gene that is functioning improperly or receptor gene for viral 
infection (Li et al. 2013a) and 3) correct the mutant gene at the 
endogenous locus (Park et al. 2014). Gene targeting at the predetermined 
endogenous locus is very intriguing method because it can preserve not 
only target gene sequences but genomic context imparted by the native 
locus. 
Engineered nucleases like ZFNs or TALENs are very useful tools 
for targeted genome editing. In recent studies, clustered regularly 
interspaced short palindromic repeats (CRISPR)/CRISPR-associated 
protein (Cas) system is used to induce site-specific DSBs to modify the 
genome in a targeted manner (Cho et al. 2013a; Cong et al. 2013; Hwang 
et al. 2013; Friedland et al. 2013; Yang et al. 2014). Naturally, 
CRISPR/Cas system is an adaptive immune system to viruses and 
plasmids in bacteria or archaea (Wiedenheft et al. 2012). CRISPR RNA 
(crRNA), trans-activating RNA (tracrRNA) and Cas9 protein in type II 
CRISPR/Cas system make ribonucleoprotein (RNP) complex and performs 
as a sequence-specific endonuclease. Recent paper showed that the 
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crRNA works like a guide-RNA whose specificity is determined by spacer 
sequences (Jinek et al. 2012), so we can use this system for targeted 
genome engineering via designing of crRNA spacer sequences.  
With the advent of molecular biology like DNA sequencing 
technology, diverse structural variations (SVs) of human genome were 
uncovered. SVs are generally defined as genomic alterations that involve 
segments of DNA larger than 1 Kb (Feuk et al. 2006) including deletion, 
insertion, duplication, translocation and inversion and these are associated 
with diverse genetic diseases (Stephens et al. 2009; Stankiewicz et al. 
2010). 
Hemophilia A (HA) is a representative genetic disease which is 
an X-chromosome-linked coagulation disorder with approximately 1 in 
every 5000 males worldwide (Graw et al. 2005). This disorder is caused 
by various genetic mutations in the X-linked coagulation factor VIII (F8) 
gene. HA can be characterized as severe (<1% activity), moderate (1–5% 
activity), and mild (5–30% activity), depending on the relative amount of 
F8 activity in the patient’s plasma (Graw et al. 2005). Almost one half of 
patients with severe HA have large DNA inversions that disrupt either 
intron 1 (Inv1) or intron 22 (Inv22) of the F8 gene (Bagnall et al. 2002; 
Naylor et al. 1993). Both Inv1 and Inv22 arise through non-allelic meiotic 
recombination between near-identical inversely oriented duplicons (i.e. 
int1h and int22h, respectively; Figure 11). Although six patients with 
hemophilia B, a less common form of X-linked bleeding disorder than 
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hemophilia A, treated with an adeno-associated virus vector (AAV) to 
deliver the F9 cDNA which encodes blood coagulation factor IX (Nathwani 
et al. 2011), this vector cannot be used to deliver the full-length F8 cDNA 
to patients with HA because AAV cannot accommodate the large size of 
the F8 cDNA(~8 kbp). Thus, gene correction at endogenous F8 locus is 
highly demanded for cure for severe hemophilia A.  
Recently, Inv1 is successfully generated in human induced 
pluripotent stem cells (iPSC) with TALEN (Park et al. 2014). Introducing 
artificial inversion of about 140-kbp chromosomal segment between 
intron1 homologous sequences in human iPSC, hemophilia A model cell 
lines were created and successfully reverted to the wild-type state by 
reversing the segment. However, Inv1 is only about 4% of severe 
hemophilia A and artificial inversion of Inv22 has not been reported yet 
which is about half of severe HA. In addition, inversion with TALEN of 
this report is not tried in actual patient iPSC. Here, I have used a 
CRISPR/Cas system as a programmable RNA-guided engineered 
nucleases (RGENs) for introducing artificial inversion of Inv1 and Inv22 
in Hela cells and patient iPSCs. Furthermore, mRNA expression of the F8 







Materials and Methods 
 
1. Preparation of RGEN-encoding plasmids and 
recombinant Cas9 protein  
Cas9-encoding plasmids were constructed as previously 
described (Cho et al. 2013a). Cas9 protein fused the HA epitope and a 
nuclear localization signal (NLS) was expressed under the control of the 
CMV promoter. U6 promoter was used to express a sgRNA as described 
previously (Cho et al. 2013a). Target sequences of each RGENs used in 
this study are shown in Table 5. 
To purify Cas9 protein, the Cas9 DNA sequence was subcloned 
into pET28-b(+) (Invitrogen) vector. Expression of recombinant Cas9 
protein containing a nuclear localization signal, the HA epitope, and the 
His-tag at the N-terminus was induced in BL21(DE3) strain using 0.5mM 
IPTG and cultured for 4hr at 25℃. The Cas9 protein was purified using 
Ni-NTA agarose beads (Qiagen), and dialyzed against 20mM HEPES pH 
7.5, 150 mM KCl, 1mM DTT, and 10% glycerol. The purified Cas9 protein 
was concentrated using Ultracel 100K cellulose column (Millipore).  
Guide RNA was in vitro transcribed using the MEGA shortscript 
T7 kit (Ambion) as previously described (Kim et al. 2014). Transcribed 
RNA was purified by phenol:chloroform extraction protocol, and purified 
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RNA was quantified using a spectrometer. 
2. Cell cultures and transfections  
HeLa (ATCC, CCL-2) was cultured in Dulbecco’s modified Eagle’
s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 
1% antibiotics. To introduce DSBs, 1×105 HeLa cells were co-
transfected with 0.5 ug of Cas9-encoding plasmid and sgRNA-encoding 
plasmid, respectively, using a Lipofectamine 2000 (Invitrogen) according 
to the manufacturer’s protocol. Human ESC (hESC) lines (H9) obtained 
from WiCell Inc., human dermal fibroblast-derived wild-type iPSCs 
(WT-iPSC Epi3 line) (Park et al. 2014), and urine-derived iPSCs 
generated in this study were maintained in hESC medium [DMEM/F12 
(Gibco) supplemented with 20% knockout serum replacement (Gibco), 1% 
nonessential amino acids (Invitrogen), and 0.1 mM 2-mercaptoethanol 
(Sigma)] including 4 ng/mL basic FGF (PeproTech) as previously 
described (Kim et al. 2010; Jang et al. 2012). To introduce the inversion 
events in urine-derived iPSCs, 1×106 cells were electroporated with 5 
ug of Cas9-encoding plasmid and sgRNA-encoding plasmid (5 ug of each 
sgRNA plasmid for intron 22 inversion), respectively, using a 
microporator system (Neon; Invitrogen). For direct delivery of Cas9 
protein into the urine-derived iPSCs, transfection was performed as 
previously described (Kim S. et al. 2014) with slight modifications. Cas9 
protein (15 ug) was mixed with 20 ug of transcribed sgRNA (20 ug of 
each sgRNA plasmid for intron 22 inversion) and incubated to formation 
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of RGEN ribonucleoprotein complexes (RNPs) for 10 min at room 
temperature. The RNPs were transfected into 2×105 iPS cells by using a 
microporator system. 
 
3. T7E1 assay and determining the frequencies of targeted 
inversion  
The T7E1 assays were performed as previously described (Kim 
et al. 2009). Briefly, the genomic region encompassing the RGEN target 
site was PCR-amplified, melted, and re-annealed to form heteroduplex 
DNA, which was treated with 5 units of T7 endonuclease 1 (New England 
Biolabs) for 15 min at 37°C and then analyzed by agarose gel 
electrophoresis.  
The frequencies of targeted corrections in the F8 locus were 
estimated by digital PCR analysis as previously described (Lee et al. 
2010). Briefly, the genomic DNA isolated from cell co-transfected with 
RGEN and sgRNA plasmids using lipofectamine 2000 (Invitrogen) was 
serially diluted, and the diluted samples were subjected to PCR analysis. 
The fraction of positive bands at each dilution points was counted and 
results were analyzed using the Extreme Limiting Dilution Analysis 




4. Validation of RGEN mediated inversion of the F8 locus in 
HeLa cells 
To validate the genome editing activities of the RGENs designed 
for this study, each RGENs were co-transfected with sgRNA expression 
plasmid into HeLa cells and their activities were measured using the T7E1 
assay and digital PCR analysis as described above. 
 
5. Isolation and expansion of urine-derived cells from 
severe hemophilia A patients  
The urine samples were collected from 11 severe patients who 
have been diagnosed with clinically confirmed by Korea Hemophilia 
Foundation Clinic. The urine-derived cells from patients were isolated as 
described previously (Zhou et al. 2012). In brief, the cells were collected 
by centrifuged at 400g for 10 min from approximately 100 ml of 
midstream urine sample. After washing twice with PBS, the cells were 
cultured in DMEM/Ham’s F12 (1:1) medium (Hyclone) supplemented 
with 10% (vol/vol) fetal bovine serum (FBS), renal epithelial cell growth 
medium (REGM) SingleQuot kit (Lonza), and 1% antibiotics. Four day 
after culturing, the cells were subsequently cultured in renal epithelial 
basal medium (Lonza) supplemented with REGM SingleQuot kit for 
expansion of urine-derived cells. For further expansion, the cells were 
splited onto gelatin-coated culture dish at 80-90% confluency. To 
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confirm of F8 genotype, genomic DNAs isolated from urine-derived 
patients cells were subjected PCR analysis with specific primer sets 
(Table 4) against intron 1 and 22 inversion of the F8 locus as described 





















Table 4. Primer pairs used in this study. 
Primer Sequence (5’ to 3’) Used for the 
experiment of 
GAPDH-F CCCCTCAAGGGCATCCTGGGCTA qPCR / RT-PCR 
GAPDH-R GAGGTCCACCACCCTGTTGCTGTA qPCR / RT-PCR 
Oct4-F CCTCACTTCACTGCACTGTA qPCR 
Oct4-R CAGGTTTTCTTTCCCTAGCT qPCR 
Lin28-F AGCCATATGGTAGCCTCATGTCCGC qPCR 
Lin28-R TCAATTCTGTGCCTCCGGGAGCAGGGTAGG qPCR 
Sox2-F TTCACATGTCCCAGCACTACCAGA qPCR 
Sox2-R TCACATGTGTGAGAGGGGCAGTGTGC qPCR 
Nanog-F TGAACCTCAGCTACAAACAG qPCR 
Nanog-R TGGTGGTAGGAAGAGTAAAG qPCR 
F8-exon1-F CTGCTTTAGTGCCACCAGAAGA RT-PCR 
F8-exon3-R GACTGACAGGATGGGAAGCC RT-PCR 
F8-exon21-F CCGGATCAATCAATGCCTGGAG RT-PCR 
F8-exon23-R ATGAGTTGGGTGCAAACGGATG RT-PCR 
Brachyury-F ATCACAAAGAGATGATGGAGGAA RT-PCR 
Brachyury-R GGTGAGTTGTCAGAATAGGTTGG RT-PCR 
GAPDH-F GAACATCATCCCTGCCTCTACTG iPS generation (PCR) 
GAPDH-R CAGGAAATGAGCTTGACAAAGTGG iPS generation (PCR) 
EBNA-1-F ATGGACGAGGACGGGGAAGA iPS generation (PCR) 





Sequence (5’ to 3’) Used for the experiment of 
1-H1 CTCCAGCCACCAGAACCA T7E1 assay 
1-H2 GCCAGTCTCTCCTTGTGTGT T7E1 assay 
1-F1 AAATCACCCAAGGAAGCACA Genotype PCR 
1-R1 TGGCATTAACGTATTACTTGGAGA Genotype PCR 
1-F2 TGCTGAGCTAGCAGGTTTAATG Genotype PCR 
1-R2 TGCTGAGCTAGCAGGTTTAATG Genotype PCR 
22-F1 TGGGGCTGTGTAAATTTGCT Genotype PCR 
22-R2 CAAACGTAGCATTACCTGATTGT Genotype PCR 
22-F2 ACAACCAGAGCAGAAATCAATGA Genotype PCR 












6. Targeted corrections of the F8 locus in patient derived-
iPSCs via RGEN plasmids  
The iPSCs were cultured onto STO feeder layer and harvested by 
treating with collagenase type IV. After washing with PBS, the cells were 
dissociated into approximately single cell level as previously described 
(Desbordes et al. 2008). These single cells were mixed with RGEN and 
sgRNA plasmids and pulsed with a voltage of 850 for 30 ms. Cells were 
then seeded onto feeder cells and allowed to grow for 10 days. To detect 
genomic inversion events occurring in F8 locus, cells from individual 
colonies were lysed and subjected to PCR as described previously (Park 
et al. 2014). PCR products were analyzed by agarose gel electrophoresis. 
Specific primer sequences are shown in Table 4. 
 
7. Isolation of clonal populations of cells, PCR analysis, and 
DNA sequencing of breakpoints  
To isolate clonal populations of corrected cells, each colony that 
had been identified by PCR as containing the desired genomic event 
(namely, correction of inversion genotype) was dissociated into single 
cells and re-seeded onto new feeder layer. After 4 rounds of passaging, 
several clones (4 clones for intron 1 correction, 3 clones for intron 22 
correction) were chosen for sequencing and further experiments. To 
determining the sequence at the breakpoints, amplified PCR products were 
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electrophoresed, and PCR products were eluted from the agarose gel as 
previously described (Park et al. 2014). 
 
8. RNA isolation, RT-PCR, and qPCR 
Total RNAs were purified from cells using TRIzol reagent 
(Invitrogen) according to the manufacturer’s instructions. cDNAs were 
synthesized from total RNAs (1ug) using the DiaStarTM cDNA synthesis 
kit (SolGent, Korea). To confirm the expression of Factor VIII, Brachyury, 
and GAPDH, PCR was performed with Ex-Taq (Takara) using the 
synthesized cDNAs as template. For qPCR, SYBR® Premix Ex-Taq 
(Takara) was used according to the manufacturer’s instructions. To 
amplification mRNA of F8 from intron 1 or intron 22 corrected lines, 
respectively, a forward primer located in exon 1 (or exon 21 for intron 1 
corrected lines) was used in combination with a reverse primer located in 
exon 3 (or exon 23 for intron 22 corrected lines). Specific primer 
sequences used for RT-PCR or qPCR are shown in Table 4. 
 
9. Generation of iPSCs from urine-derived cells and in 
vitro differentiation  
 Less than 3 time passage, the urine-derived cells were used for 
iPS cell (iPSC) generation. Episomal reprogramming vectors were used 
as previously reported (Okita et al. 2011) for iPSC generation from two 
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urine-derived patients cells (referred as Pa1-UC and Pa2-UC) among 
three patients cells. Sendai virus purchased from Invitrogen was used for 
iPSC generation from third urine-derived patient cells (referred as Pa3-
UC) according to the manufacturer’s instructions. Seven iPSC colonies 
that looked similar to human ES cells were picked up mechanically, and 
were further cultured for characterization. In vitro differentiation of the 
iPSCs into three germ layers was performed as previously described 
(Sugii et al. 2010; Jang et al. 2011). For induction of embryoid bodies 
(EBs), iPS colonies on feeder cells were partially dissociated using 
collagenase type IV (Invitrogen). EBs were transferred to Petri dishes 
(SPL Lifesciences, Korea) and cultured in hESC medium without basic 
fibroblast growth factor (bFGF) but supplemented with 5% FBS for ten 
days. Spontaneous differentiation of EBs into cells representing the three 
germ layer lineages was detected by immunostaining with appropriate 
antibodies. To induce differentiation of iPSCs into the mesoderm lineage, 
we used a previously described report (Yoo et al. 2013) with slight 
modifications. Briefly, EBs were transferred to Petri dishes and cultured 
in hESC medium excluding basic fibroblast growth factor (bFGF) but 
supplemented with 20 ng/mL bone morphogenic protein-4 (BMP4, R&D 
Systems) and 10 ng/mL Activin A (PeproTech). On day 3, EBs were 
attached onto Matrigel-coated dishes and were cultured for an additional 
3 days in same medium described above. On day 6 of differentiation, cells 
that had differentiated into the mesoderm lineage were harvested for 
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determination of F8 gene expression. 
 
10. Characterization of iPSCs  
Alkaline phosphatase (AP) activity was measured with the 
leukocyte alkaline phosphatase staining kit (Sigma) according to the 
manufacturer’s instructions. To confirm the urine-derived cells origin of 
iPSC lines, short tandem repeat (STR) was analysed. STR loci were 
amplified from genomic DNA samples isolated from iPSC lines and their 
parental cells using the AmpFISTR PCR reaction system (Applied 
Biosystems). PCR-based STR analysis was peformed at Human Pass Inc. 
(Korea). For karyotype analysis, A G-banding analysis of chromosomes 
from the each iPSCs was performed at the GenDix Inc. (Korea). 
Immunostaining of ES cell markers was carried out as described 
previously (Park et al. 2014). DAPI (4’, 6-Diamidino-2-Phenylindole, 
Vector Laboratories) was used for nuclei visualization. The images were 
captured and analyzed using an Olympus IX71 microscope or FSX system. 
 
11. Analysis of off-target effects 
 Potential off-target sites of RGENs used in this study were 
searched in silico (Bae et al. 2014). RGEN-encoding plasmids were 
transfected in HeLa cells. Several potential off-target sites that similar to 
the RGEN target site were selected and amplified by PCR. The T7E1 
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analysis was performed as described above. 
 
12. Ethical statement  
Yonsei University Institutional Review Board approval (IRB # 4-
2012-0028) was obtained for the generation and analyses of urine-
derived iPS cells from the hemophilia A patients. All volunteers who 
participated in this study have signed written informed consent to donate 



















Figure 11. Two inversions in the F8 gene. Schematic view of proposed 
model against the intron 1 and 22 inversions found in patients with severe 













1. Targeted inversion of intron 1 of F8 via RGEN in Hela 
cells 
First, I designed a RGEN for targeted reversion of intron1 in the 
F8 gene (RGEN01) which recognize 20bp sequences in the homologous 
region of intron1. There are two homologous regions of intron1 in the 
human genome (here after int1h-1 and int1h-2); one is in the intron1 of 
the F8 gene, and another is in the intergenic region located approximately 
140-kb from the F8 gene. Thus, this RGEN cut two regions together and 
inversion of 140kb genomic fragment between these sites could be 
occurred (Figure 12; Park et al. 2014).  
To test the activity of this RGEN01, I transfected Cas9 plasmid 
and crRNA plasmid into Hela cells. I found that RGEN01 generated 
mutations most actively with an incidence of 34% at the target site (Figure 
13A). In addition, the inversion specific bands between two homologous 
regions were detected in cells transfected with RGEN 01 (Figure 13B). 
Small deletion and insertions were found in breakpoint junction by 
sequence analysis from these PCR products (Figure 13 C, D). This 140-
kb inversion that involves the intron 1 homolog was generated with a 
frequency of 3.1 % (for intron 1 homolog 1) and 2.2 % (for intron 1 




Figure 12. Schematic view of targeted inversion of intron1 in the F8 gene 
in Hela cells. Two RGEN target sites recognized by one crRNA in the 
















Figure 13. Targeted correction of F8 intron 1 locus in Hela cells. (a) 
Mutations at the RGEN 01 target site within intron 1 of F8 were estimated 
in Hela cells by the T7E1 assay. Asterisks indicate the predicted position 
of DNA bands cleaved by T7E1. (b) PCR products corresponding to 
inversion genotypes. (c, d) DNA sequences of two homolog (here named 
int1 homolog 1 and 2) and breakpoint junctions in RGEN01 transfected 



















Figure 14. Frequencies of targeted intron1 inversion. The digital PCR was 
performed for estimating the frequency of targeted inversion. Genomic 
DNA was isolated from the HeLa cells transfected with RGEN01 and was 
serially diluted. Estimated frequency of targeted inversions events 
created via RGEN01 was measured by digital PCR analysis (Lee H. et al. 






2. Targeted inversion of intron22 of F8 via RGEN in Hela 
cells 
Intron 22 inversions is occurred by homologous recombination 
between three intron 22 homologous copies (refer to int22h-1, int22h-
2, and int22h-3, respectively) (Lakich et al. 1993; Bagnall et al. 2006). 
The intron 22 homolog 1 (int22h-1) region is located in the F8 gene locus, 
and others located approximately 500-kb (int22h-2) and 600-kb 
(int22h-3) apart from int22h-1, respectively (Figure 15). Unlike 
RGEN01 cutting two homologous regions of intron 1, RGEN that targets 
within int22h is able to cut three homologous copies, respectively. Then, 
two genomic fragments can be generated and variable unwanted (i.e. only 
one of them is inverted) clones could be more appeared. To solve this 
problem, I generated two specific RGENs (termed RGEN 02 and RGEN 03) 
that target nearby of int22h-1 or int22h-3 (Figure 15), and then tested 
their activity for genome engineering in Hela cell. RGEN02 and RGEN03 
created indel mutations with an incidence of 44% and 32% at the each 
target sites, respectively (Figure 16A).  
Next, I tested whether 600-kb genomic inversion between 
int22h-1 and int22h-3 could be generated in Hela cells containing wild-
type genome structure. As shown in Figure 16B, this inversion was 
detected in cells that transfected with both RGENs. In each breakpoint 
junction, indels and large deletions were found by sequence analysis from 
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these PCR products (Figure 16C). This event was induced with a 
frequency of 2.2% (for breakpoint junction nearby intron 22 homolog 1) 
and 1.5% (for breakpoint junction nearby intron 22 homolog 3) in Hela 























Figure 15. Schematic view of targeted inversion of intron22 in the F8 gene 
in Hela cells. Two target sites of each RGENs and PCR primers used to 



















Figure 16. Targeted correction of the F8 intron 22 locus in Hela cells. (a) 
Mutations at RGEN 02 and RGEN 03 target sites were estimated in Hela 
cells by the T7E1 assay. Asterisks indicate the predicted position of DNA 
bands cleaved by T7E1. (b) PCR products corresponding to inversion 
genotypes. (c, d) DNA sequences of two breakpoint junctions in 





















Figure 17. Frequencies of targeted intron22 inversion. The digital PCR 
was performed for estimating the frequency of targeted inversion as in 
Figure 14. Genomic DNA was isolated from the HeLa cells transfected 
with both of RGEN02 and 03 and was serially diluted. Estimated frequency 
of targeted inversions events created via RGENs was measured by digital 






3. Genotype of urine-derived HA patient cells  
To create iPSCs from hemophilia A patients, the genotype 
screening is performed to search intron 1 and 22 inversions from 11 
unrelated korean patient cells with severe hemophilia A. Only 1 patient 
has intron 1 inversion, and 3 patients have intron 22 inversion. These 
incidences found in here coincide approximately with previously reports 
(Lakich et al. 1993; Kim et al. 2012). After screening, 3 patient cells were 
selected (namely, Pa1, Pa2, and Pa3) for further investigation. As showed 
in Figure 18, Pa1 and Pa2 cells showed wild-type in intron-1 locus of F8, 
but Pa3 cells showed inversion in this locus. In contrast, Pa1 and Pa2 
patient cells presented a genotype of intron-22 inversion, but Pa3 cells 
showed wild-type. These results show that each patient cells harbor only 
one among the intron-1 or intron-22 inversion. In addition, PCR amplicon 
used with specific primer set, H2F and H1R, does not showed in Pa1 and 
Pa2 cells (Figure 18). This means that those cells have the genomic 
inversion between homolog 1 and 3 among the three homologies not 









(by Park CY. in Yonsei Univ.) 
Figure 18. Genotype of the F8 gene in patient cells. Genomic DNA was 
isolated from human dermal fibroblasts (WT) and hemophilia A patient-
derived urine cells (Pa1, Pa2, and Pa3). PCR analysis was subjected to 
identify of the intron 1 (left) and 22 (right) inversions using the specific 













4. Generation of iPS cells from urine-derived patient cells 
 Next, each iPSCs from 3 urine-derived patient cells were 
generated (Figure 19). Through both method electroporation of episomal 
vector or infection of Sendai virus containing the reprogramming factors, 
it was able to obtain embryonic stem cell (ESC)-like colonies derived 
from urine cells (Figure 19A). Among them, total of 7 colonies (termed 
Epi1 to Epi7 in case of Pa1- and Pa2-iPSCs, respectively) derived by 
episomal vector from Pa1 and Pa2 urinary cells and total of 5 colonies 
(termed Sen1 to Sen5) derived by Sendai virus from Pa3 urinary cells 
were propagated. In case used episomal vector, the EBNA-1 sequence 
was amplified through PCR analysis to check the absence of residual 
vector in these lines after 8 passages. All lines selected were did not 
contained the EBNA-1 sequence (Figure 19B) and were showed high 
alkaline phosphatase activities (Figure 19C). After initial 
characterizations, one line from each patient iPSCs (namely, Epi5, Epi7, 
and Sen2 from Pa1-, Pa2-, and Pa3-iPSCs, respectively) is selected for 
further study. Each iPSC lines had a normal karyotype (Figure 19D). 
Immunostaining analysis revealed that the typical ESC marker proteins 
were well expressed in these lines (Figure 19E).  
Next, the mRNA level of pluripotent marker genes are confirmed 
such as Oct4, Sox2, Lin28, and Nanog in selected lines. As shown in Figure 
19F, those expressed at similar levels in iPSC lines with the human ES 
cell line, H9. In addition, in vitro differention potential of these lines was 
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investigated. It was found that marker proteins for three germ layers were 
detected in the differentiated cells by immunostaining analysis (Figure 
19G). These data show that all selected lines derived from urinary cells 













































Figure 19. Generation of HA patient-specific iPSCs from urine cells. (a) 
Morphology of the expanded urine cells (upper) and iPSC clones (lower). 
Scale bar, 500um. (b) Detection of an episomal vector sequence (EBNA-
1) that remained in established iPSC lines (Epi1 to Epi7 of Pa1-iPSCs and 
Pa2-iPSCs, respectively). The GAPDH gene was used as a internal 
control for isolated total DNA. Total DNA isolated from the each urine 
cells before (naive) and after electroporation (Day 5) was used as 
negative and positive controls for episomal vector DNA. (c) Alkaline 
phosphatase staining of the indicated iPSCs lines. Scale bar, 500 um. (d) 
Karyotype analyses were performed on chromosomes from the indicated 
iPSC lines. (e) The expression of OCT4, NANOG and TRA-1-80, which 
are human ESC specific markers, was detected by immunocytochemistry. 
DAPI signals indicate the total cell presence in the image. Scale bar, 
100um. (f) Quantitative real-time PCR (qPCR) was performed for 
detection of endogenous OCT4, SOX2, LIN28, and NANOG mRNAs in the 
indicated cell lines. The expression level of those genes was normalized 
to GAPDH expression. (g) Detection of marker proteins representing 
ectoderm (Nestin), mesoderm [α-smooth muscle actin (α-SMA)], and 
endoderm [α-fetoprotein (AFP)] in each lines by immunostaining with 
specific antibodies. DAPI signals indicate the total cell presence in the 




5. Targeted corrections of the F8 gene from patient iPSCs 
with intron 1 inversions 
To investigate availability of targeted inversion via RGENs as 
gene therapeutic way, RGEN01 was electroporated to repair of 140-kb 
inverted segment into the Pa3-iPSCs, and pulsed cells were further 
cultured to form colony. By PCR analysis, the specific bands for two 
homologies were detected using genomic DNA samples isolated from each 
colony. 8 colonies among total 120 colonies (6.7% frequency) have 
positive PCR bands for the two homologies by PCR screening. Four 
colonies were then further cultured to derive single cell clones. These 
corrected clones likewise wild-type cells produced homology specific 
PCR bands, while patient-derived urine cells and iPSCs did not produce 
these bands (Figure 20A).  
Next, the sequence of these PCR products were analyzed to 
confirm the genotype. Indel mutations were not found in three clones, but 
13-bp deletions at RGEN01 target sites in two homologies were found in 













Figure 20. Targeted correction of F8 intron 1 locus from intron 1 inverted 
patient iPSCs. (a) PCR analysis of genomic DNA from four corrected 
clones (Co-1 to Co-4). Genomic DNAs were isolated from the urine-
derived cells of intron 1 inversion patient (Pa3-U) or wild-type iPSCs 
(WT) served as positive controls for the inversion or normal genotypes, 
respectively. (b) DNA sequences of two homolog (here named int1 
homolog 1 and 2) and breakpoint junctions at the indicated clones. The 

















6. Targeted corrections of the F8 gene from patient iPSCs 
with intron 22 inversions 
To introduce targeted re-inversion of intron22 in patient iPSCs, 
RGEN02 and RGEN03 were delivered in Pa1-iPS cells by electroporation. 
Five colonies of 135 (3.7% frequency) showed corrected PCR products 
for the two inversion breakpoint junctions. Three corrected clones were 
then derived after further culturing. By genotype PCR, these clones have 
corrected segment (namely, 600-kbp inverted between nearby int22h1 
and int22h3), while patient-derived iPSCs involved intron 22 inversion do 
not have (Figure 21A). Small deletions or insertions were found at two 
RGEN target sites might be resulted by error-prone DSB repair via NHEJ 
(Figure 21B). These results show that 600-kbp inverted segment found 



















Figure 21. Targeted correction of F8 intron 22 locus from intron 22 
inverted patient iPSCs. (a) PCR analysis of genomic DNA from three 
corrected clones (Co-1 to Co-3). Genomic DNAs isolated from the wild-
type iPSCs (WT) or intron 22 inverted patient iPSCs (Pa1) served as 
normal genotypes or positive controls for the inversion, respectively. (b) 
DNA sequences of breakpoint junctions in the indicated clones. Each 
RGEN target sequence is underlined, respectively. Dashes indicate 
deleted bases. A lowercase letter indicates inserted bases. Two blue 
















7. mRNA expression of F8 in cells differentiated from 
corrected clones  
It has been reported that endothelial cells which is derived from 
mesoderm were important source in the F8 gene expression (Shahani et 
al. 2010). Therefore, the patient or corrected iPSCs were differentiated 
into mesoderm and investigated the expression of F8 mRNA through an 
RT-PCR and qPCR analysis. First, it was determined whether amplicons 
of F8 exon 1 to 2 could be detect in cells differentiated from Pa3-iPSCs 
with intron 1 inversion. As expected, no amplicons of F8 exon 1 to 2 were 
detected in these cells, although the cells differentiated from Pa3-iPSCs 
could differentiate successfully into mesoderm as shown by the 
expression of Brachyury, a mesoderm cell marker gene (Figure 22). 
However, those amplicons were accurately detected in cells differentiated 
from the wild-type and two corrected lines (termed Co-1 and Co-2) 
repaired from Pa3-iPSCs.  
Next, it was confirmed whether amplicons of F8 exon 22 to 23 
could be detect in cells differentiated from Pa1- and Pa2-iPSCs with 
intron 22 inversion. Amplicons of F8 exon 22 to 23 were undetected in 
these cells, although the cells differentiated from those iPSCs could 
differentiate successfully into mesoderm (Figure 22). On the other hand, 
those amplicons were successfully detected in cells differentiated from 
the wild-type and three corrected lines (termed Co-1 to Co-3) repaired 
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from Pa1-iPSCs. By sequencing analysis, it was found that the splicing 
events between exon 1 and 2, or exon 22 and 23 from Pa3 and Pa1 
corrected lines, respectively, could occur precisely without any unwanted 
genetic mutations (Figure 22C). These results prove that the integrity of 
the F8 gene could correct accurately from patient iPSCs with intron 1 or 

























Figure 22. Expression of the F8 gene in corrected clones. (a) F8 
expression in cells differentiated from intron-1 corrected clones. RT-
PCR (upper) and qPCR (lower) was used to detect expression of F8 and 
mesoderm marker gene (Brachyury) in cells derived from wild-type 
iPSCs (WT), intron-1 inverted patient iPSCs (Pa3), and corrected clones 
(Co-1 and Co-2). GAPDH expression was used as a loading control. (b) 
F8 expression in cells derived from intron-22 corrected clones. RT-PCR 
(upper) and qPCR (lower) was used to detect expression of F8 and 
mesoderm marker gene (Brachyury) in cells derived from wild-type 
iPSCs (WT), intron-22 inverted patients iPSCs (Pa1 and Pa2), and 
corrected clones (Co-1, Co-2 and Co-3) which are originated from Pa1-
iPSCs. (c) The sequences between exon 1 to 2 or exon 22 to 23 in wild-












8. Targeted correction of the F8 gene using RGEN 
ribonucleoproteins (RNPs) in patient-iPSCs  
Recently, it has been reported that RGEN RNPs can introduce into 
the fibroblast and ES cells via direct delivery and induce efficiently indels 
at target sites (Kim et al. 2014). Because this method has advantage in 
safety aspect than plasmid encoding RGENs, this method was also used 
for correction of the F8 gene from patient-iPSCs. The RGEN RNPs were 
transfected into two patient iPSCs containing intron 1 or intron 22 
inversion (Pa3- and Pa2-iPSCs, resfectively), and then total genomic 
DNA samples were isolated at 4 day after transfection. The correction-
specific PCR band was cloned and sequenced. As expected, precisely 
corrected sequence was found with no indels in Pa3-iPSCs with intron 1 
inversion (Figure 23), suggesting the event of NAHR in RGEN-mediated 
genomic correction. Moreover, repaired sequences of the 600-kb 
inverted segment in F8 locus were showed in Pa2-iPSCs with intron 22 
inversion via a direct delivery of RGEN RNPs (Figure 23). The joining 
seamlessly and indels at the each breakpoint junction were revealed by 












Figure 23. Targeted correction of the F8 gene using RGEN 
ribonucleoproteins (RNPs) in patient-specific iPSCs. DNA sequences of 
each breakpoint junctions for the inversion events in the intron 1 (a) or 
intron 22 (b) regions. A direct delivery of RGEN RNPs was performed by 
electroporation into the intron 1 (Pa3-iPSCs) or intron 22 (Pa2-iPSCs) 
inverted cells. Total DNA isolated from the each iPSCs and sequenced. 
Each RGEN target sequence is underlined, respectively. Dashes indicate 
deleted bases. A lowercase letter indicates inserted bases. Two blue 
arrows indicate cleavage sites. In cases in which a sequence was detected 















9. Analysis of RGEN off-target effect 
In recent years, many groups reported that RGENs had off-target 
cleavage effect in human cells (Fu et al. 2013; Hsu et al. 2013; Pattanayak 
et al. 2013). Off-target cleavage can be induced at sites that are highly 
homologous to on-target sites. As mutations in off-target sites are very 
serious problem especially in gene therapy, I tested whether there are 
indel mutations at potential off-target sites induced by NHEJ with off-
target cleavage of RGENs. Potential off-target sites of RGENs used in 
this study were searched in silico (Bae et al. 2014; Table 5). T7E1 assay 
of those sites showed that there is no mutations at potential off-target 
















Figure 24. Analysis of RGEN off-target effect. Potential off-target sites 
of RGENs used in this study were searched in silico (Bae et al. 2014). 
RGEN-encoding plasmids were transfected in HeLa cells. Several 
potential off-target sites that similar to the RGEN target site were 
selected and amplified by PCR. The T7E1 analysis was performed to 








Table 5. Potential off-target sites of RGENs in this study. Identical 
nucleotides are in uppercase. PAM, Protospacer Adjacent Motif.  
Locus Seqeunces PAM 
RGEN01 GGTCCCCGGGGTTGTGCCCC TGG 
R1off1 tGgCCCCtGGGTTGTGCCCC AGG 
R1off2 GGTCCCtGGGGTgtTGCCCC TGG 
R1off3 GGgCCCCGGGGTccTGCCCC AGG 
RGEN02 TGGTAAGAGTACCGGTGGGA AGG 
R2off1 TaGTAAtAGTAaCGGTGGGA GGG 
R2off2 TGGTgAGAGTAggGGTGGGA GGG 
R2off3 TGGaAAGAGaACCGGTGtGA AGG 
R2off4 TGGggAGAGTACCGGcGGGA AGG 
R2off5 TGGTcAGAGTAaCaGTGGGA TGG 
R2off6 TGGTAAaAGTAaCtGTGGGA TGG 
RGEN03 CACAAATTCTCAATATGCCC AGG 
R3off1 CcCAAATcCTCAATATGCCC CGG 
R3off2 CACAAATTCTCAATtTGCaC AGG 
R3off3 CACAAAgcCTCAAcATGCCC TGG 
R3off4 gAaAAATTCTaAATATGCCC TGG 
R3off5 tACAAATTtTCcATATGCCC TGG 
R3off6 aACAtATTCTCAAaATGCCC AGG 




Hemophilia A is one of the most common genetic bleeding 
disorders caused by various mutations in the F8 gene. In this study, I 
designed CRISPR/Cas system as engineered nucleases targeting inverted 
sites in the F8 gene. These RGENs can induce double strand break at 
target sites very efficiently (up to 44%) in Hela cells tested by T7E1 
assay. Targeted inversion via these RGENs is also very efficient (up to 
6.7%) to generate single clone with ease. Importantly, corrected clones 
from severe hemophilia A patient iPSCs can regenerate F8 mRNA like as 
wild type cells. 
Induced DSB via programmable endonucleases at precise target 
loci can be repaired by non-homologous end-joining (NHEJ) or 
homologous recombination (HR) resulting mutations and chromosomal 
rearrangements (Bibikova et al. 2003; Kim et al. 2009; Kim et al. 2011b; 
Miller et al. 2011; Brunet et al. 2009; Lee et al. 2010; Lee et al. 2012). 
Thus, engineered nucleases are emerging as powerful tools for gene 
therapy. Although ZFNs and TALENs were well studied artificial 
nucleases (Kim et al. 2009; Kim et al. 2011b; Reyon et al. 2012; Kim et 
al. 2013), RGEN is more easy method to design and customizing. To 
create new RGEN, only expression vector of sgRNA should be replaced 
by cloning with 20-bp target sequence without changing the Cas9 protein 
component. Furthermore, for making RNP complex to deliver into cells 
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which is a novel method reducing off-target cleavage (Kim et al. 2014), 
Cas9 protein should not be purified every time because target recognition 
function fully relies on the guide RNA. Actually, RGEN system is broadly 
used in cells (Cho et al. 2013a; Cong et al. 2013; Jinek et al. 2013) and 
many species (Cho et al. 2013b; Hwang et al. 2013; Sung et al. 2014; 
Dickinson et al. 2013; Friedland et al. 2013; Gratz et al. 2013; Li et al. 
2013b; Nekrasov et al. 2013; Shan et al. 2013).  
As previously reported, targeted cleavage at two endogenous loci 
in the genome of human cells can result in deletions, inversions and 
duplications (Lee et al. 2011). In previous report and this study, inversion 
of intron1 in the F8 gene is corrected by reversion of segment between 
intron1 and corresponding homologous sequences located far upstream of 
the F8 gene (Park et al. 2014). Frequent detection of seamless junction 
in cleavage sites imply this junction might be repaired by NAHR more than 
error prone NHEJ. 
Inversion of intron22 in the F8 gene is more complicated. Because 
there are two more homologous sequences corresponding intron22 in the 
upstream region of the F8 gene, targeted cleavage inside homologous 
sequences result in DSB at three loci total and, as a result, two genomic 
fragments are created. As repair of two genomic fragments lead to many 
combination of deletions, inversions and duplications, the chance to get 
perfectly corrected clones of intron22 inversion is probably very low. 
Actually, I designed RGEN targeting inside of homology of intron22, but 
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corrected clones had not been created because of low efficiency. Instead, 
by targeting the locus a bit aside of homology, I could induce cleavage at 
two sites in the genome, and efficiently create corrected clone of intron22 
in patient iPSC whose expression of F8 mRNA is normal like wild-type 
cells although DNA sequence nearby junction is different from that of wild 
type cells. 
Targeting with RGEN in non-homologous sequences also has a 
benefit on detection of inversion. Homologous sequence of intron22 
reaches a length of 10kb and additionally 50kb in case of between int22h2 
and int22h3, indeed, standard PCR method cannot be used for genotyping. 
Although inverse shifting-polymerase chain reaction (IS-PCR) approach 
can detect inversion of intron22 (Rossetti et al. 2008), this method is not 
suitable for early screening of iPSC clones because it needs lots of 
genomic DNA (~2ug). In this study, two RGENs target unique sites 
individually and, consequently, corrected clones were selected by 
standard PCR with ease.  
In summary, RGENs can be used to induce targeted inversions 
efficiently in Hela cells and human iPSCs that represent severe hemophilia 
A. Inverted 140kbp genomic DNA segment of intron1 inversion patient 
cells, and about 600kbp that of intron22 inversion patient cells were 
successfully reverted via induced DBS at precise target loci. Furthermore, 
mRNA expression of the F8 gene in corrected clones is recovered like as 
normal cells. Although in vivo study of these corrected clones is not yet 
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demonstrated, this study showed that artificial inversion approach via 
engineered nucleases can be used for autologous stem cell therapy to treat 
severe hemophilia A patients. RGEN-induced genomic rearrangements 
will not only suggest a superb gene therapeutic approach for many genetic 
diseases but provide an experimental platform to study the molecular 
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 Transcription activator-like effector nucleases (TALEN) 과 
RNA-guided engineered nuclease (RGEN) 은 최근에 도입된 유전체 공학
의 도구로써 폭넓게 쓰이고 있다. TALEN은 DNA 염기 서열을 하나씩 특이
적으로 인식하는 transcription activator-like effector protein 에 FokI 
cleavage domain 을 붙인 인공적인 제한효소이다. 본 연구에서는 Pibf1 과 
Sepw1 유전자에 각각 특이적으로 작용할 수 있는 TALEN 을 제작하였고, 
생쥐 세포주에 주입하였을 때 유전자에 변이가 성공적으로 도입되는 것을 확
인할 수 있었다. 나아가 실제 생쥐의 수정란에 TALEN mRNA를 도입하였을 
때 매우 효율적으로 녹아웃 된 생쥐를 얻을 수 있었다. RGEN은 세균이나 고
세균에서 외부 도입 유전자를 절단하는 기능을 가진 CRISPR/Cas 시스템을 
이용한 유전자 가위이다. 본 연구에서는 RGEN 을 사용하여 혈우병의 주요 
원인으로 알려진 F8 유전자의 역위를 교정하는데 성공하였다. 먼저 Hela 세
포주에서 F8 의 intron1 번과 22번에 작용하는 RGEN 을 각각 도입하였을 
때 성공적으로 600kbp 에 이르는 염기 서열의 역위가 이루어진 것을 관찰하
였다. 그리고 실제 혈우병을 가지고 있는 환자의 세포로부터 유도만능줄기세
포(iPSC)를 얻은 후 해당 RGEN을 도입하여 F8 유전자의 mRNA 가 다시 
정상적으로 발현되는 교정된 세포를 성공적으로 얻을 수 있었다. 이처럼 
TALEN 과 RGEN 은 손쉽고 빠르게 제작할 수 있는 매우 효율적인 유전자 
가위이므로 유전자의 특성 연구와 같은 기초 과학으로부터 유전자 교정이나 
치료에 이르기까지 폭넓게 이용될 것으로 기대되고 있다. 
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